Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Qianqian Zhou, Shengru Zhou, Huizi Xiong, Jianqiu Yang, Ziliang Yang, Naihui Zhou, Jinzhu Mao & Min Li. (2023) A Case of Paradoxical Reactions to Biologic Therapy for Psoriasis. Clinical, Cosmetic and Investigational Dermatology 16, pages 1493-1497.
Read now
Read now
Marta Pérez-De-Lis, Soledad Retamozo, Alejandra Flores-Chávez, Belchin Kostov, Roberto Perez-Alvarez, Pilar Brito-Zerón & Manuel Ramos-Casals. (2017) Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry). Expert Opinion on Drug Safety 16:11, pages 1255-1271.
Read now
Read now
Mio Nakamura, Kristina Lee, Rasnik Singh, Tian Hao Zhu, Benjamin Farahnik, Michael Abrouk, John Koo & Tina Bhutani. (2017) Eczema as an adverse effect of anti-TNFα therapy in psoriasis and other Th1-mediated diseases: a review. Journal of Dermatological Treatment 28:3, pages 237-241.
Read now
Read now
Christoforos Vlachos, Georgios Gaitanis, Konstantinos H Katsanos, Dimitrios K Christodoulou, Epameinondas Tsianos & Ioannis D Bassukas. (2016) Psoriasis and inflammatory bowel disease: links and risks. Psoriasis: Targets and Therapy 6, pages 73-92.
Read now
Read now
Articles from other publishers (30)
Minnie Au, Georgina Heddle, Edward Young, Emma Ryan, Scott Graf, Derrick Tee & Hamish Philpott. (2022) Anti‐tumour necrosis factor‐induced skin rashes in inflammatory bowel disease: a systematic review and evidence‐based management algorithm. Internal Medicine Journal 53:10, pages 1854-1865.
Crossref
Crossref
Michael T Dolinger, Priya Rolfes, Elizabeth Spencer, Guillaume Stoffels, David Dunkin & Marla C Dubinsky. (2022) Outcomes of Children with Inflammatory Bowel Disease who Develop Anti-tumour Necrosis Factor-induced Skin Reactions. Journal of Crohn's and Colitis 16:9, pages 1420-1427.
Crossref
Crossref
Kevin Cesa, Catherine Cunningham, Tyler Harris & Whitney Sunseri. (2022) A Review of Extraintestinal Manifestations & Medication-Induced Myocarditis and Pericarditis in Pediatric Inflammatory Bowel Disease. Cureus.
Crossref
Crossref
Wenhui Xie, Shiyu Xiao, Hong Huang & Zhuoli Zhang. (2022) Incidence of and Risk Factors for Paradoxical Psoriasis or Psoriasiform Lesions in Inflammatory Bowel Disease Patients Receiving Anti-TNF Therapy: Systematic Review With Meta-Analysis. Frontiers in Immunology 13.
Crossref
Crossref
N. Urganci, M. Sakar, O. Yalcín & D. Kalyoncu. (2022) Henoch-Schönlein purpura induced by infliximab for Crohn’s disease: A case report and literature review. Revista de Gastroenterología de México (English Edition) 87:1, pages 110-112.
Crossref
Crossref
N. Urganci, M. Sakar, O. Yalcín & D. Kalyoncu. (2022) Púrpura de Henoch-Schönlein inducida por infliximab para enfermedad de Crohn: reporte de un caso y revisión de la literatura. Revista de Gastroenterología de México 87:1, pages 110-112.
Crossref
Crossref
Shaden Mahmmod, Johannes P D Schultheiss, Ad A van Bodegraven, Gerard Dijkstra, Lennard P L Gilissen, Frank Hoentjen, Maurice W M D Lutgens, Nofel Mahmmod, Andrea E van der Meulen–de Jong, Lisa J T Smits, Adriaan C I T L Tan, Bas Oldenburg & Herma H Fidder. (2021) Outcome of Reverse Switching From CT-P13 to Originator Infliximab in Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases 27:12, pages 1954-1962.
Crossref
Crossref
Meiqi Yang, Weixin Liu, Qiuping Deng, Zeng Liang & Qin Wang. (2021) The incidence of psoriasis among smokers and/or former smokers inflammatory bowel diseases patients treated with tumor necrosis factor antagonist. Medicine 100:42, pages e27510.
Crossref
Crossref
P. A. Makarchuk, E. Yu. Lomakina & E. A. Belousova. (2020) Ustekinumab in patients with Crohn’s disease with extraintestinal manifestations (psoriasis). Meditsinskiy sovet = Medical Council:15, pages 121-126.
Crossref
Crossref
A. Al‐Janabi, A.C. Foulkes, K. Mason, C.H. Smith, C.E.M. Griffiths & R.B. Warren. (2020) Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review. Journal of the European Academy of Dermatology and Venereology 34:7, pages 1440-1448.
Crossref
Crossref
Farzad Alinaghi, Hasan Göcker Tekin, Johan Burisch, Jashin J Wu, Jacob P Thyssen & Alexander Egeberg. (2020) Global Prevalence and Bidirectional Association Between Psoriasis and Inflammatory Bowel Disease—A Systematic Review and Meta-analysis. Journal of Crohn's and Colitis 14:3, pages 351-360.
Crossref
Crossref
Wiebke Sondermann, Saskia Herz, Elsa Sody & Andreas Körber. (2019) Dermatologische Komplikationen unter Therapie mit Biologika bei entzündlichen Autoimmunerkrankungen. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 17:10, pages 1029-1038.
Crossref
Crossref
Wiebke Sondermann, Saskia Herz, Elsa Sody & Andreas Körber. (2019) Dermatological complications of therapy with biologics in inflammatory autoimmune diseases. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 17:10, pages 1029-1037.
Crossref
Crossref
Olivier Courbette, Camille Aupiais, Jerome Viala, Jean-Pierre Hugot, Baptiste Louveau, Lucienne Chatenoud, Emmanuelle Bourrat & Christine Martinez-Vinson. (2019) Infliximab Paradoxical Psoriasis in a Cohort of Children With Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology & Nutrition 69:2, pages 189-193.
Crossref
Crossref
Charles N Bernstein, Eric I Benchimol, Alain Bitton, Sanjay K Murthy, Geoffrey C Nguyen, Kate Lee, Jane Cooke-Lauder & Gilaad G Kaplan. (2019) The Impact of Inflammatory Bowel Disease in Canada 2018: Extra-intestinal Diseases in IBD. Journal of the Canadian Association of Gastroenterology 2:Supplement_1, pages S73-S80.
Crossref
Crossref
Francisco J. Melo & Sofia Magina. (2018) Clinical management of Anti-TNF-alpha-induced psoriasis or psoriasiform lesions in inflammatory bowel disease patients: a systematic review. International Journal of Dermatology 57:12, pages 1521-1532.
Crossref
Crossref
Dalal Almutairi, Christopher Sheasgreen, Adam Weizman & Afsaneh Alavi. (2018) Generalized Pustular Psoriasis Induced by Infliximab in a Patient With Inflammatory Bowel Disease. Journal of Cutaneous Medicine and Surgery 22:5, pages 507-510.
Crossref
Crossref
Adam V. Weizman, Robyn Sharma, N. M. Afzal, Wei Xu, Scott Walsh, Joanne M. Stempak, Geoffrey C. Nguyen, Ken Croitoru, A. Hillary Steinhart & Mark S. Silverberg. (2018) Stricturing and Fistulizing Crohn’s Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease. Digestive Diseases and Sciences 63:9, pages 2430-2438.
Crossref
Crossref
J. M. Bae, H. H. Lee, B.-I. Lee, K.-M. Lee, S. H. Eun, M.-L. Cho, J. S. Kim, J. M. Park, Y.-S. Cho, I. S. Lee, S. W. Kim, H. Choi & M.-G. Choi. (2018) Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study. Alimentary Pharmacology & Therapeutics 48:2, pages 196-205.
Crossref
Crossref
. (2018) Manage cutaneous adverse effects associated with tumour necrosis factor inhibitors with topical corticosteroids and oral antibiotics. Drugs & Therapy Perspectives 34:7, pages 317-321.
Crossref
Crossref
Júlia Vide, Filipa Osório, Miguel Costa-Silva, Sofia Lopes, Filomena Azevedo, Cláudia Camila Dias, Sofia Magina & Fernando Magro. (2018) Cutaneous Morbidity Among Inflammatory Bowel Disease Patients: A Cohort Study. Journal of Crohn's and Colitis 12:4, pages 442-451.
Crossref
Crossref
P. Andrade, S. Lopes, R. Gaspar, A. Nunes, S. Magina & G. Macedo. (2018) Anti-Tumor Necrosis Factor-α-Induced Dermatological Complications in a Large Cohort of Inflammatory Bowel Disease Patients. Digestive Diseases and Sciences 63:3, pages 746-754.
Crossref
Crossref
M. L. Barclay & L. K. Stamp. (2018) Editorial: vedolizumab as a treatment and cause of extra-intestinal manifestations of inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 47:4, pages 535-536.
Crossref
Crossref
Uni Wong & Raymond K. Cross. 2018. Treatment of Inflammatory Bowel Disease with Biologics. Treatment of Inflammatory Bowel Disease with Biologics
231
260
.
Takashi Ohya, Masakatsu Yanagimachi, Kentaro Iwasawa, Shuichiro Umetsu, Tsuyoshi Sogo, Ayano Inui, Tomoo Fujisawa & Shuichi Ito. (2017) Childhood-onset inflammatory bowel diseases associated with mutation of Wiskott-Aldrich syndrome protein gene. World Journal of Gastroenterology 23:48, pages 8544-8552.
Crossref
Crossref
Faseeha C. Peer, Andrew Miller, Paul Pavli & Kavitha Subramaniam. (2017) Paradoxical psoriasiform reactions of anti-tumour necrosis factor therapy in inflammatory bowel disease patients. Internal Medicine Journal 47:12, pages 1445-1448.
Crossref
Crossref
Siegfried Segaert & Caroline Hermans. (2017) Clinical Signs, Pathophysiology and Management of Cutaneous Side Effects of Anti-Tumor Necrosis Factor Agents. American Journal of Clinical Dermatology 18:6, pages 771-787.
Crossref
Crossref
Gang Peng, Huanyu Guan, Xiaoming Wang & Yue Shi. (2017) Simultaneous determination of 14 active constituents of Shengjiang Xiexin decoction using ultrafast liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Acta Pharmaceutica Sinica B 7:2, pages 193-201.
Crossref
Crossref
Fabiana Andréa Moura, Kívia Queiroz de Andrade, Orlando Roberto Pimentel de Araújo, Valéria Nunes-Souza, Juliana Célia de Farias Santos, Luiza Antas Rabelo & Marília Oliveira Fonseca Goulart. (2016) Colonic and Hepatic Modulation by Lipoic Acid and/or N-Acetylcysteine Supplementation in Mild Ulcerative Colitis Induced by Dextran Sodium Sulfate in Rats. Oxidative Medicine and Cellular Longevity 2016, pages 1-18.
Crossref
Crossref
Steven D. Billings & Jenny CottonSteven D. Billings & Jenny Cotton. 2016. Inflammatory Dermatopathology. Inflammatory Dermatopathology
23
42
.